Morning or afternoon? timing of immunotherapy infusion may affect esophageal cancer outcomes

NCT ID NCT07452601

Recruiting now Disease control Sponsor: Tang-Du Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether giving immunotherapy (adebrelimab) plus chemotherapy at different times of day changes how well it works for people with esophageal cancer. 90 participants will be split into three groups based on infusion timing before surgery. The main goal is to see if timing affects the chance of a complete tumor response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adebrelimab plus nab-paclitaxel and cisplatin
What this could lead to: If timing matters, this could improve how well immunotherapy works for esophageal cancer, potentially leading to better tumor shrinkage before surgery.
What could go wrong: This is a small, early-phase study (90 people) focused on timing, not a new drug. Results may not change practice, and the combination has typical chemo side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Tangdu Hospital Affiliated to the Fourth Military Medical University
RECRUITING

Xi'an, Shannxi, 710038, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.